Document is current

Article History

Received: 1 October 2021

Accepted: 2 May 2023

First Online: 8 June 2023

Competing interests

: The funding that contributed to the subject matter of this manuscript is described as follows: Broad Institute SPARC award, National Institutes of Health grant (U19 AI082630), Adelson Medical Research Foundation, National Human Genome Research Institute grant (RM1HG006193), support from the Center for Cell Circuits at the Broad Institute (HG006193) and Cancer Research Institute award (4071). A.M.A., K.V.G., J.S., M.B., P.C.B. and N.H. are inventors on a licensed, pending international patent application, having serial number PCT/US2021/037226, filed by Broad Institute of MIT and Havard, Massachusetts General Hospital and Massachusetts Institute of Technology, directed to certain subject matter related to the MAS-seq method described in this manuscript. Broad Institute of MIT and Harvard and Pacific Biosciences of California entered into a collaboration agreement relating to this research subsequent to the submission of this manuscript. A.A.P. is a venture partner and employee of GV. He has received funding from Verily, Microsoft, Illumina, Bayer, Pfizer, Biogen, Abbvie, Intel and IBM. M.S.F. receives funding from Bristol-Myers Squibb. G.M.B. has served on SAB and on the steering committee for Nektar Therapeutics. She has SRAs with Olink Proteomics and Palleon Pharmaceuticals. She served on SAB and as a speaker for Novartis. N.H. holds equity in BioNTech and is a founder and equity holder of Danger Bio. P.C.B. is a consultant to and/or holds equity in companies that develop or apply genomic or genome editing technologies: 10× Genomics, General Automation Lab Technologies/Isolation Bio, Celsius Therapeutics, Next Gen Diagnostics LLC, Cache DNA, Concerto Biosciences, Stately Bio, Ramona Optics, Bifrost Biosystems and Amber Bio. P.C.B.’s group receives research funding from industry for unrelated work. The remaining authors declare no competing interests.